Bluefin Biomedicine
Initial Transaction Details
Transaction Date
July 2025
Purpose of Financing
Venture
Stage of Company
Mid Stage
Structure of Financing
Equity
Bluefin Biomedicine is a privately held company focused on the detection of novel cancer antigens and the development of next-generation medicines for the treatment of cancer. They are using proprietary, cutting-edge protein detection methods to interrogate complex tumor specimens and discover differentially expressed cancer antigens that can be targeted with antibody therapies. Their focus is on cancers with clear unmet medical need and building a robust portfolio of therapeutic candidates that address those needs.
Website